[an error occurred while processing this directive] | [an error occurred while processing this directive]
Post-treatment prognostic score model establishment and stratified therapy for newly diagnosed metastatic nasopharyngeal carcinoma
Lan yuhong*, Tian Yunming, Bai Li, Zeng Lei, Xiao Weiwei, Lu Taixiang, Han Fei
*Department of Radiation Oncology, Huizhou Municipal Centre Hospital of Sun Yat-sen University;Huizhou City People’s Hospital, Huizhou 516000, ChinaCorresponding authors:Tian Yunming,Email:tianyunming123@126.com;Han Fei,Department of Radiation Oncology,Cancer Center,Sun Yat-sen University,State Key Laboratory of Oncology in South China,Guangzhou 510060,China;Email:hanfei@sysucc.org.cn
Abstract Objective To establish a post-treatment prognostic score model for newly diagnosed metastatic nasopharyngeal carcinoma, and to investigate the feasibility of stratified therapy. Methods A total of 263 eligible patients with newly diagnosed metastatic nasopharyngeal carcinoma from 2002 to 2010 were enrolled as subjects. The primary tumor was treated with conventional radiotherapy, three-dimensional conformal radiotherapy, or intensity-modulated radiotherapy, and radiation areas included nasopharyngeal tumor and cervical lymphatic drainage region. The metastatic bone tumor was mainly treated with conventional external radiotherapy, while the metastatic liver or lung tumor was mainly treated with surgical resection, radiotherapy, or radiofrequency ablation. The first-line therapy for most of patients was cisplatin-based combination chemotherapy. Factors including the general characteristics, tumor status, and therapy for patients were involved in multivariate analysis, and a prognostic model was established based on the n value (HR=en) of the prognostic factors. Results The factors influencing the overall survival (OS) in patients were a Karnofsky performance score (KPS) not higher than 70(P=0.00), multiple organ metastases (P=0.00), combination with liver metastasis (P=0.00), a number of metastases not less than 2(P=0.00), a level of lactate dehydrogenase (LDH) higher than 245 IU/L (P=0.00), a number of chemotherapy cycles ranging between 1 and 3(P=0.00), a poor response for metastatic tumor (stable disease or progressive disease)(P=0.00), and primary tumor not treated with radiotherapy (P=0.01). Based on the prognostic score, patients were divided into low-risk group (0-1.5 points), intermediate-risk group (2.0-6.5 points), and high-risk group (≥7.0 points), and the 5-year OS rates in the three groups were 59.0%, 25.1%, and 0%, respectively. Conclusions The prognosticscore model based on the KPS, serum level of LDH, multiple organ metastases, combination with liver metastasis, and number of metastases can effectively predict the survival in patients. Active treatment including at least 4 chemotherapy cycles and radiotherapy for primary tumor can prolong the survival time of patients in the low-and intermediate-risk groups. However, patients in the high-risk group were mainly treated with palliative radiotherapy due to no improvement in the survival by radiotherapy for primary tumor.
Lan yuhong*,Tian Yunming,Bai Li et al. Post-treatment prognostic score model establishment and stratified therapy for newly diagnosed metastatic nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 421-426.
Lan yuhong*,Tian Yunming,Bai Li et al. Post-treatment prognostic score model establishment and stratified therapy for newly diagnosed metastatic nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 421-426.
[1] Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma[J]. Semin Cancer Biol,2002,12(6):421-429. [2] Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma[J]. Cancer Epidemiol Biomarkers Prev,2006,15(10):1765-1777. [3] Lee AW, Ng WT, Chan YH, et al. The battle against nasopharyngeal cancer[J]. Radiother Oncol,2012,104(3):272-278.DOI:10.1016/j.radonc.2012.08.001. [4] Yeh SA, Tang Y, Lui CC, et al. Treatment outcomes of patients with AJCC stage ⅠVC nasopharyngeal carcinoma:benefits of primary radiotherapy[J]. Jpn J Clin Oncol,2006, 36(3):132-136. [5] 王成涛,曹卡加,李茵,等.鼻咽癌远处转移的预后分析[J].癌症,2007,26(2):212-215. [6] 韩露,林少俊,李夷民,等.46例首诊伴远处转移鼻咽癌的预后分析[J].中华放射肿瘤学杂志,2009,18(3):170-172.DOI:10.3760/cma.j.issn.1004-4221.2009.03.170. [7] Teo PM, Kwan WH, Lee WY, et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma[J]. Cancer,1996,77(12):2423-2431. [8] Khanfir A, Frikha M, Ghorbel A, et al. Prognostic factors in metastatic nasopharyngeal carcinoma[J]. Cancer Radiother,2007,11(8):461-464. [9] Setton J, Wolden S, Caria N, Lee N. Definitive treatment of metastatic nasopharyngeal carcinoma:Report of 5 cases with review of literature[J]. Head Neck,2012, 34(5):753-757.DOI:10.1002/hed.21608. [10] Hui EP, Leung SF, Au JS, et al. Lung metastasis alone in nasopharyngeal carcinoma:a relatively favorable prognostic group. A study by the Hong Kong nasopharyngeal carcinoma study group[J]. Cancer,2004,101(2):300-306. [11] Ong YK, Heng DM, Chung B, et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma[J]. Eur J Cancer,2003,39(11):1535-1541. [12] Tian YM, Zeng L, Wang FH, et al. Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis:a retrospective study for the management of treatment[J]. Radiat Oncol,2013,8(1):272.DOI:10.1186/1748-717X-8-272. [13] Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer:univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients[J]. J Clin Oncol,1995,13(5):1221-1230. [14] Polee MB, Hop WC, Kok TC, et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy[J]. Br J Cancer,2003,89(11):2045-2050. [15] Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Tumour and Angiogenesis Research Group. Lactate dehydrogenase-5(LDH-5) over expression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis[J]. Br J Cancer,2003,89(5):877-885. [16] Liaw CC, Wang CH, Huang JS,et al. Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma[J]. Acta Oncol,1997,36(2):159-164. [17] Zhou GQ, Tang LL, Mao YP, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma:a predictor of poor prognosis and subsequent liver metastasis[J]. Int J Radiat Oncol Biol Phys,2012,82(2):359-365. [18] Hellman S, Weichselbaum RR. Oligometastases[J]. J Clin Oncol,1995,13(1):8-10. [19] Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases[J]. J Clin Oncol,1997,15(3):938-946. [20] Salama JK, Milano MT. Radical Irradiation of Extracranial Oligometastases[J]. J Clin Oncol, 2014,32(26):2902-2912. [21] Fandi A, Bachouchi M, Azli N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type[J].J Clin Oncol,2000,18(8):1324-1330.
2015, Vol. 24 
